In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - AMGEN-20180130
Protocol Summary
- Protocol No
- AMGEN-20180130
- Principal Investigator
- Michael Burke
- Phase
- IV
- Title
- Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia
(ALL) who Have Been Treated With Either Blinatumomab or Chemotherapy, Followed by Transplantation
- Associated Disease(s)
-
Bone Marrow Transplant and Cellular Therapy
- Description (Summary)
- The purpose of this project is to learn more about long-term safety in patients who have been treated with either blinatumomab or SOC chemotherapy before going into alloHSCT. Blinatumomab has been fully approved by Food and Drugs Agency (FDA) in 2017 and by European Medicines Agency (EMA) in 2018 for the treatment of adults and children with relapsed/refractory Philadelphia chromosome negative (Ph-) B-cell acute lymphoblastic leukemia (ALL).
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
